

References

1. Statistics ABo. National Health Survey: First Results, 2017-2018. 2018.
2. PriceWaterhouseCooper. Weighing the cost of obesity: A case for action. 2015.
3. Diabetes Prevention Program Research G, Knowler WC, Fowler SE, Hamman RF, Christophi CA, Hoffman HJ, et al. 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. *Lancet*. 2009;374(9702):1677-86.
4. Council NHaMR. Clinical practice guidelines for the management of overweight and obesity in adults, adolescents and children in Australia. 2013.
5. Bouchard C, Tremblay A, Despres JP, Nadeau A, Lupien PJ, Theriault G, et al. The response to long-term overfeeding in identical twins. *The New England journal of medicine*. 1990;322(21):1477-82.
6. Stunkard AJ, Harris JR, Pedersen NL, McClearn GE. The body-mass index of twins who have been reared apart. *N Engl J Med*. 1990;322(21):1483-7.
7. Montague CT, Farooqi IS, Whitehead JP, Soos MA, Rau H, Wareham NJ, et al. Congenital leptin deficiency is associated with severe early-onset obesity in humans. *Nature*. 1997;387(6636):903-8.
8. Stunkard AJ, Sorensen TI, Hanis C, Teasdale TW, Chakraborty R, Schull WJ, Schulsinger F. An adoption study of human obesity. *The New England journal of medicine*. 1986;314(4):193-8.
9. Vaisse C, Clement K, Guy-Grand B, Froguel P. A frameshift mutation in human MC4R is associated with a dominant form of obesity. *Nat Genet*. 1998;20(2):113-4.
10. Huypens P, Sass S, Wu M, Dyckhoff D, Tschop M, Theis F, et al. Epigenetic germline inheritance of diet-induced obesity and insulin resistance. *Nat Genet*. 2016;48(5):497-9.
11. Ravelli GP, Stein ZA, Susser MW. Obesity in young men after famine exposure in utero and early infancy. *N Engl J Med*. 1976;295(7):349-53.
12. Australia O. Rethink Obesity: A media guide on how to report on obesity. 2015.
13. Fruh SM, Nadglowski J, Hall HR, Davis SL, Crook ED, Zlomke K. Obesity Stigma and Bias. *J Nurse Pract*. 2016;12(7):425-32.
14. Markovic TP, Natoli SJ. Paradoxical nutritional deficiency in overweight and obesity: the importance of nutrient density. *The Medical journal of Australia*. 2009;190(3):149-51.
15. Council NHaMR. Australian Guide to Healthy Eating
<http://www.eatforhealth.gov.au/guidelines/australian-guide-healthy-eating> [
16. Council NHaMR. Australian Dietary Guidelines. 2013.
17. Hu T, Mills KT, Yao L, Demanelis K, Eloustaz M, Yancy WS, Jr., et al. Effects of low-carbohydrate diets versus low-fat diets on metabolic risk factors: a meta-analysis of randomized controlled clinical trials. *Am J Epidemiol*. 2012;176 Suppl 7:S44-54.
18. Sacks FM, Bray GA, Carey VJ, Smith SR, Ryan DH, Anton SD, et al. Comparison of weight-loss diets with different compositions of fat, protein, and carbohydrates. *The New England journal of medicine*. 2009;360(9):859-73.
19. Gudzone KA, Doshi RS, Mehta AK, Chaudhry ZW, Jacobs DK, Vakil RM, et al. Efficacy of commercial weight-loss programs: an updated systematic review. *Ann Intern Med*. 2015;162(7):501-12.
20. Sumarithran P, Proietto J. Safe year-long use of a very-low-calorie diet for the treatment of severe obesity. *Med J Aust*. 2008;188(6):366-8.
21. Astbury NM, Aveyard P, Nickless A, Hood K, Corfield K, Lowe R, Jebb SA. Doctor Referral of Overweight People to Low Energy total diet replacement Treatment (DROPLET): pragmatic randomised controlled trial. *BMJ*. 2018;362:k3760.
22. Christensen P, Meinert Larsen T, Westerterp-Plantenga M, Macdonald I, Martinez JA, Handjiev S, et al. Men and women respond differently to rapid weight loss: Metabolic outcomes of a multi-centre intervention study after a low-energy diet in 2500 overweight, individuals with pre-diabetes (PREVIEW). *Diabetes, obesity & metabolism*. 2018;20(12):2840-51.
23. Lean ME, Leslie WS, Barnes AC, Brosnahan N, Thom G, McCombie L, et al. Primary care-led weight management for remission of type 2 diabetes (DiRECT): an open-label, cluster-randomised trial. *Lancet*. 2018;391(10120):541-51.
24. Lean MEJ, Leslie WS, Barnes AC, Brosnahan N, Thom G, McCombie L, et al. Durability of a primary care-led weight-management intervention for remission of type 2 diabetes: 2-year results of the DiRECT open-label, cluster-randomised trial. *Lancet Diabetes Endocrinol*. 2019;7(5):344-55.
25. Hocking SL, Markovic TP, Lee CMY, Picone TJ, Gudorf KE, Colagiuri S. Intensive Lifestyle Intervention for Remission of Early Type 2 Diabetes in Primary Care in Australia: DiRECT-Aus. *Diabetes care*. 2023.
26. Proietto J. Obesity and weight management at menopause. *Australian Family Physician*. 2017;46(6):368-70.

27. Government A. More than half of all Australian adults are not active enough. 2014.
28. Practitioners RACoG. Smoking, nutrition, alcohol, physical activity (SNAP): A population health guide to behavioural risk factors in general practice. 2015.
29. Kang JG, Park CY, Kang JH, Park YW, Park SW. Randomized controlled trial to investigate the effects of a newly developed formulation of phentermine diffuse-controlled release for obesity. *Diabetes Obes Metab.* 2010;12(10):876-82.
30. Munro JF, MacCuish AC, Wilson EM, Duncan LJ. Comparison of continuous and intermittent anorectic therapy in obesity. *Br Med J.* 1968;1(5588):352-4.
31. Garvey WT, Ryan DH, Look M, Gadde KM, Allison DB, Peterson CA, et al. Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study. *The American journal of clinical nutrition.* 2012;95(2):297-308.
32. Torgerson JS, Hauptman J, Boldrin MN, Sjostrom L. XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. *Diabetes Care.* 2004;27(1):155-61.
33. Pi-Sunyer X, Astrup A, Fujioka K, Greenway F, Halpern A, Krempf M, et al. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. *The New England journal of medicine.* 2015;373(1):11-22.
34. Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, Nauck MA, et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. *The New England journal of medicine.* 2016;375(4):311-22.
35. Davies MJ, Aronne LJ, Caterson ID, Thomsen AB, Jacobsen PB, Marso SP, et al. Liraglutide and cardiovascular outcomes in adults with overweight or obesity: A post hoc analysis from SCALE randomized controlled trials. *Diabetes, obesity & metabolism.* 2018;20(3):734-9.
36. Billes SK, Sinnayah P, Cowley MA. Naltrexone/bupropion for obesity: an investigational combination pharmacotherapy for weight loss. *Pharmacol Res.* 2014;84:1-11.
37. Hong K, Herrmann K, Dybala C, Halseth AE, Lam H, Foreyt JP. Naltrexone/Bupropion extended release-induced weight loss is independent of nausea in subjects without diabetes. *Clin Obes.* 2016;6(5):305-12.
38. Greenway FL, Fujioka K, Plodkowski RA, Mudaliar S, Guttadauria M, Erickson J, et al. Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet.* 2010;376(9741):595-605.
39. Hollander P, Gupta AK, Plodkowski R, Greenway F, Bays H, Burns C, et al. Effects of naltrexone sustained-release/bupropion sustained-release combination therapy on body weight and glycemic parameters in overweight and obese patients with type 2 diabetes. *Diabetes Care.* 2013;36(12):4022-9.
40. Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. *The New England journal of medicine.* 2021;384(11):989.
41. Lincoff AM, Brown-Frandsen K, Colhoun HM, Deanfield J, Emerson SS, Esbjerg S, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. *The New England journal of medicine.* 2023.
42. Perkovic V, Tuttle KR, Rossing P, Mahaffey KW, Mann JFE, Bakris G, et al. Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes. *The New England journal of medicine.* 2024.
43. Newsome PN, Buchholtz K, Cusi K, Linder M, Okanoue T, Ratziu V, et al. A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis. *The New England journal of medicine.* 2020.
44. Loomba R, Abdelmalek MF, Armstrong MJ, Jara M, Kjaer MS, Krarup N, et al. Semaglutide 2.4 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial. *Lancet Gastroenterol Hepatol.* 2023.
45. Nauck MA, Quast DR, Wefers J, Pfeiffer AFH. The evolving story of incretins (GIP and GLP-1) in metabolic and cardiovascular disease: A pathophysiological update. *Diabetes, obesity & metabolism.* 2021;23 Suppl 3:5-29.
46. Kramer CK, Leitao CB, Pinto LC, Canani LH, Azevedo MJ, Gross JL. Efficacy and safety of topiramate on weight loss: a meta-analysis of randomized controlled trials. *Obesity reviews : an official journal of the International Association for the Study of Obesity.* 2011;12(5):e338-47.
47. Neoh SL, Sumithran P, Haywood CJ, Houlihan CA, Lee FT, Proietto J. Combination phentermine and topiramate for weight maintenance: the first Australian experience. *The Medical journal of Australia.* 2014;201(4):224-6.

48. O'Neil PM, Birkenfeld AL, McGowan B, Mosenzon O, Pedersen SD, Wharton S, et al. Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial. *Lancet*. 2018;392(10148):637-49.
49. Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, et al. Tirzepatide Once Weekly for the Treatment of Obesity. *New England Journal of Medicine*. 2022.
50. Loomba R, Hartman ML, Lawitz EJ, Vuppalanchi R, Boursier J, Bugianesi E, et al. Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver Fibrosis. *The New England journal of medicine*. 2024.
51. Malhotra A, Grunstein RR, Fietze I, Weaver TE, Redline S, Azarbarzin A, et al. Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity. *New England Journal of Medicine*. 2024.
52. Rubino F, Nathan DM, Eckel RH, Schauer PR, Alberti KG, Zimmet PZ, et al. Metabolic Surgery in the Treatment Algorithm for Type 2 Diabetes: A Joint Statement by International Diabetes Organizations. *Diabetes Care*. 2016;39(6):861-77.
53. W. H. O. Expert Consultation. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. *Lancet*. 2004;363(9403):157-63.
54. Piers LS, Rowley KG, Soares MJ, O'Dea K. Relation of adiposity and body fat distribution to body mass index in Australians of Aboriginal and European ancestry. *Eur J Clin Nutr*. 2003;57(8):956-63.
55. Ross R, Neeland IJ, Yamashita S, Shai I, Seidell J, Magni P, et al. Waist circumference as a vital sign in clinical practice: a Consensus Statement from the IAS and ICCR Working Group on Visceral Obesity. *Nature reviews Endocrinology*. 2020;16(3):177-89.
56. Ryan DH, Yockey SR. Weight Loss and Improvement in Comorbidity: Differences at 5%, 10%, 15%, and Over. *Curr Obes Rep*. 2017;6(2):187-94.
57. Dixon JB, Egger GJ, Finkelstein EA, Kral JG, Lambert GW. 'Obesity paradox' misunderstands the biology of optimal weight throughout the life cycle. *Int J Obes (Lond)*. 2015;39(1):82-4.
58. In: Rasmussen KM, Yaktine AL, editors. *Weight Gain During Pregnancy: Reexamining the Guidelines*. The National Academies Collection: Reports funded by National Institutes of Health. Washington (DC)2009.
59. NSW GH. Weight gain during pregnancy
http://www.gethealthynsw.com.au/assets/pdf/resources/GHS_Fact_Sheet_Weight_Gain_During_Pregnancy_online_Final.pdf [
60. Allied Health Sciences Section Ad Hoc Nutrition C, Aills L, Blankenship J, Buffington C, Furtado M, Parrott J. ASMBs Allied Health Nutritional Guidelines for the Surgical Weight Loss Patient. *Surg Obes Relat Dis*. 2008;4(5 Suppl):S73-108.
61. Grima M, Dixon JB. Obesity--recommendations for management in general practice and beyond. *Aust Fam Physician*. 2013;42(8):532-41.
62. Mechanick JI, Youdim A, Jones DB, Garvey WT, Hurley DL, McMahon MM, et al. Clinical practice guidelines for the perioperative nutritional, metabolic, and nonsurgical support of the bariatric surgery patient--2013 update: cosponsored by American Association of Clinical Endocrinologists, the Obesity Society, and American Society for Metabolic & Bariatric Surgery. *Endocr Pract*. 2013;19(2):337-72.
63. Welbourn R, Dixon J, Barth JH, Finer N, Hughes CA, le Roux CW, et al. NICE-Accredited Commissioning Guidance for Weight Assessment and Management Clinics: a Model for a Specialist Multidisciplinary Team Approach for People with Severe Obesity. *Obes Surg*. 2016;26(3):649-59.
64. Fothergill E, Guo J, Howard L, Kerns JC, Knuth ND, Brychta R, et al. Persistent metabolic adaptation 6 years after "The Biggest Loser" competition. *Obesity (Silver Spring)*. 2016;24(8):1612-9.
65. le Roux CW, Astrup A, Fujioka K, Greenway F, Lau DCW, Van Gaal L, et al. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial. *Lancet*. 2017;389(10077):1399-409.